Kim N. Chi, MD, on Adding Apalutamide to Androgen-Deprivation Therapy for Metastatic Castration-Sensitive Prostate Cancer

Posted: Monday, June 17, 2019

Kim N. Chi, MD, of BC Cancer, discusses treating metastatic castration-sensitive prostate cancer by adding apalutamide to androgen-deprivation therapy now that phase III findings from the TITAN study showed improved radiographic progression-free and overall survival.